|
Match
|
Document |
Document Title |
|
|
7491797 |
PRO6308 polypeptide
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7491706 |
Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof
The present invention provides a series of artificial CpG-containing single-stranded oligodeoxynucleotides (ODNs), each of which is consisted of single-stranded oligodeoxynucleotide DNA molecule...
|
|
|
7491701 |
Peptides that bind to HSP90 proteins
YSLPGYMVKKLLGA (SEQ ID NO:1) and its active analogs, compositions, and methods of use.
|
|
|
7491692 |
Methods for making and delivering Rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
The present invention provides methods for making, delivering and using formulations that combine a therapeutically active agent(s) (such as for example a Rho antagonist(s)) and a flowable carrier...
|
|
|
7491689 |
Compositions comprising the biologically active peptide YSL
Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced...
|
|
|
7491690 |
Self-assembly and mineralization of peptide-amphiphile nanofibers
Peptide-amphiphilic compositions capable of self-assembly into useful nanostructures.
|
|
|
7491396 |
Process for the preparation of hypoallergenic mosaic antigens
A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE...
|
|
|
7491696 |
Proteolysis resistant active VEGF
The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino...
|
|
|
7491691 |
Connective tissue stimulating peptides
Novel peptides are described which comprise an amino acid motif selected from the group consisting of “PG”, “GP”, “PI” and “IG” and having up to 10 amino acids upstream and/or...
|
|
|
7491697 |
Muteins of fibroblast growth factor 21
The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are...
|
|
|
7491394 |
Cytotoxic factors for modulating cell death
Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for...
|
|
|
7488793 |
Isolated peptide which binds to HLA-Cw*07 and uses thereof
Peptides which consist of amino acid sequences found in MAGEA3 bind to HLA-Cw*07 molecules to form T cell epitopes. The therapeutic and diagnostic ramifications of this are the subject of this...
|
|
|
7488716 |
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2...
|
|
|
7488717 |
Methods of inhibiting chemokine binding to chemokine receptors
Novel peptides or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed...
|
|
|
7488711 |
Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
Methods for inhibiting endothelial cell growth and angiogenesis, and suppressing tumor growth using calreticulin, fragments of calreticulin and variants of calreticulin are provided. Such methods...
|
|
|
7488478 |
Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for...
|
|
|
7488710 |
SFRP and peptide motifs that interact with SFRP and methods of their use
This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also...
|
|
|
7485618 |
FGF-5 supported and binding peptides
The present invention provides peptides and supported peptides that bind to FGF-5.
|
|
|
7485617 |
Osteoinductive materials
The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic roteins, wherein depending on the subject matter the proteins may be dimeric or...
|
|
|
7485698 |
Pharmaceutical composition for preventing or treating malignant glioma
An object of the present invention is to provide a novel malignant glioma antitumor agent and malignant glioma antitumor agent for animals, and in order to achieve this object, in the present...
|
|
|
7485304 |
Non-toxic mucosal adjuvant
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic...
|
|
|
7485301 |
Methods of treating inflammatory disease using antibodies which bind GPR-9-6
The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The...
|
|
|
7485619 |
Antimicrobial agent
The present application discloses a therapeutic antimicrobial composition comprising mucocidin antimicrobial peptides or analogue or fragments thereof having antimicrobial activity.
|
|
|
7485616 |
Methods of investigating, diagnosing, and treating amyloidosis
The present invention provides a therapeutic method for removing amyloid fibrils from a patient. The present invention also provides a transgenic animal that develops systemic AA amyloidosis within...
|
|
|
7485321 |
Peyer's patch and/or M-cell targeting ligands
Purified synthetic polypeptide ligands for targeting pharmaceutical agents and carriers comprising such agents to intestinal epithelial tissue, especially Peyer's patch and/or M-Cell tissue. Also...
|
|
|
7482426 |
C23 Polypeptides
Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of...
|
|
|
7482326 |
Endothelial-monocyte activating polypeptide III
A human EMAP III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing...
|
|
|
7482433 |
Peptides and compounds that bind to the IL-5 receptor
Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVX 3 VEX 4 ARCPTCK, EGYVX 3 VEX 4 ARCPTCK, EGYVX 3 VEX 4 ARCPTCR, GYVX 3 VEX 4 ARCPTCG, EGYVX 3 VEX 4 ARCPTCG,...
|
|
|
7482318 |
Protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp 10pk) has anti-apoptotic activity
The invention relates to a method of treating neuronal apoptosis in a mammal using nucleic acid encoding HSV-2 ICP10PK, or a polypeptide encoded thereby. The invention further relates to a method...
|
|
|
7482014 |
Melanoma therapy
Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective...
|
|
|
7482320 |
Modulation of smooth muscle cell proliferation
There is provided a novel use for vascular endothelial growth factor, herein designated VEGF-X, and a CUB domain present in the sequence of VEGF-X, which enhance smooth muscle cell proliferation...
|
|
|
7482319 |
Vault and vault-like carrier molecules
A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like...
|
|
|
7482322 |
Plexin family-like polypeptide, and uses thereof
The present invention is directed to a novel plexin family like DNA, a gene containing the DNA, novel polypeptide encoded by the DNA, a recombinant protein containing the polypeptide or...
|
|
|
7482442 |
HEMCM42 nucleic acids
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells,...
|
|
|
7482329 |
Single domain TDF-related compounds and analogs thereof
The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing,...
|
|
|
7482139 |
Variants of antithrombin III
Disclosed are compositions and methods related to variant antithrombin III molecules.
|
|
|
7482008 |
Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several...
|
|
|
7482430 |
Compositions and methods relating to multimeric and oligomeric soluble fragments of the TWEAK receptor
The present invention provides methods and compositions relating to fusion proteins comprising multimeric soluble TWEAK receptor fragments and an oligomerization domain. Such fusion proteins are...
|
|
|
7482001 |
Method of administering and using VEGF inhibitors for the treatment of non small cell lung cancer
A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the...
|
|
|
7482018 |
Use of oligomers and polymers for drug solubilization, stabilization, and delivery
The invention relates to the use of oligomers and polymers capable of rendering insoluble drugs soluble, protecting unstable drugs, and facilitating the delivery of drugs to their site of action....
|
|
|
7479480 |
Peptides that promote lipid efflux
Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided...
|
|
|
7479283 |
Acellular pertussis vaccine comprising a combination of the 69 kDa and the filamentous haemagglutinin antigens of Bordetella pertussis
An acellular vaccine is provided which in use provides protection against Bordetella pertussis infections. The vaccine is based on the synergistic combination of two antigenes from B. pertussis...
|
|
|
7479281 |
Botulinum toxin for treating postherpetic neuralgia
Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The...
|
|
|
7479479 |
CNGH0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses
Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids...
|
|
|
7479478 |
Human parathyroid hormone modifications, preparation and use
The present invention is related to synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28). Some of the peptides of the invention are at least 90% identical to a peptide...
|
|
|
7479484 |
Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention...
|
|
|
7479282 |
Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID...
|
|
|
7476651 |
Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a...
|
|
|
7476648 |
Vessel embolic material comprising hydrogel and therapy with the use thereof
According to the present invention, a vessel embolic material comprising a hydrogel containing a cell growth factor, which is applicable to embolic operations for various vascular disorders,...
|
|
|
7476649 |
Antiproliferative and antiviral proteins and peptides
The present invention relates to peptides and proteins which may be used to inhibit infection or cell proliferation. It is based, at least in part, on the discovery of peptides and proteins...
|